Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 10/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629570 | 0.90 | PYGL (0.52) | PYGLNPC1RAB9ASMN1; SMN2CNR1 | |
| SCHEMBL6629383 | 0.88 | PYGL (0.59) | PYGLNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6631272 | 0.85 | CA2 (0.55) | PYGLNPC1ALDH1A1 | |
| SCHEMBL6629024 | 0.82 | PYGL (0.48) | PYGLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6629202 | 0.82 | PYGL (0.57) | PYGLNPC1RAB9A | |
| SCHEMBL6632773 | 0.81 | CNR1 (0.50) | PYGLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6629148 | 0.80 | PYGL (0.49) | PYGLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6630421 | 0.79 | RAB9A (0.50) | PYGLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6630739 | 0.79 | PYGL (0.53) | PYGLNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6631294 | 0.79 | PYGL (0.55) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | claimed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | claimed |
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | PYGL 3/4885NPC1 3131/4885RAB9A 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.